Phosphagenics has a new VP of Business Development and Commercial Operations. From the POH website
Aleksandar Stojanovic (PhD)
Vice President, Business Development & Commercial Operations
Dr Stojanovic joined Phosphagenics in February 2014. He has 10 years of broad commercial experience, during which he has advised, worked for, or partnered with, more than 30 pharmaceutical, biotech and medical device companies on various aspects of business development, commercialization, marketing, pricing, market access and corporate strategy.
Dr Stojanovic served as Senior Director of Global New Compound Marketing at Grunenthal GmbH, managing the global commercial development of two pipeline pain molecules. He received a PhD in Pharmacology & Toxicology from Dartmouth College (USA) and BS degrees in Chemistry and Cell & Structural Biology from the University of Illinois (USA).
The Grunenthal connection is very interesting. Grunenthal licenses its tamper-resistant technology to Purdue (OxyContin) and Endo (Opana).
http://phosphagenics.com/About_Us/Management.aspx
new us appointment
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $3.607K | 1.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 102396408 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 21041400 | 12 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVE (ASX) Chart |